Olaparib Rejection By NICE Inconsistent With Personalized Medicine Goals, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma company says NICE’s rejection of its PARP inhibitor “is inconsistent” with EMA’s goal to accelerate access of personalized medicines and the U.K. government’s ambitions for promoting targeted medicines. Meanwhile Roche, Novartis, Boehringer Ingelheim and Bayer get green lights for their latest therapies from the cost-effectiveness watchdog.